Nivolumab and Ipilimumab in the Treatment of Metastatic Uveal Melanoma: A Single-Center Experience
Joint Authors
Abdel Karim, Nagla
Karivedu, Vidhya
Eldessouki, Ihab
Taftaf, Ahmad
Zhu, Zheng
Makramalla, Abouelmagd
Source
Case Reports in Oncological Medicine
Issue
Vol. 2019, Issue 2019 (31 Dec. 2019), pp.1-8, 8 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2019-04-17
Country of Publication
Egypt
No. of Pages
8
Main Subjects
Abstract EN
Background.
Metastatic uveal melanoma (MUM) is associated with a poor prognosis, with a median overall survival (OS) of 4–15 months.
Despite new insights into the genetic and molecular background of MUM, satisfactory systemic treatment approaches are currently lacking.
The study results of innovative treatment strategies are urgently needed.
Patients and Methods.
This was a retrospective case series of 8 patients with MUM managed at the University of Cincinnati between January 2015 and January 2018.
The immune-related Response Evaluation Criteria in Solid Tumors (irRECIST) 1.1 criteria were used for patient evaluation, and magnetic resonance imaging was used for evaluation at treatment checkpoints.
Objective.
To assess the clinical outcome of patients with MUM treated with a combination of checkpoint inhibitors.
Results.
The series included eight patients, six men and two women, with MUM.
Their median age at MUM diagnosis was 69 (range, 55–77) years.
All patients were treated with ipilimumab and nivolumab combination along with transarterial chemoembolization (TACE), followed by nivolumab maintenance and monthly TACE procedures.
The majority of patients had a partial response or stable disease.
Two of the patients had partial response, while four others had stable disease.
Two other patients experienced disease progression.
Conclusion.
We report the outcomes of eight patients with MUM treated with the combination of ipilimumab and nivolumab.
We report the clinical outcome and toxicity associated with this treatment approach.
Further studies are warranted to explore immunotherapy in MUM.
These findings support the consideration of immunotherapy in MUM.
American Psychological Association (APA)
Karivedu, Vidhya& Eldessouki, Ihab& Taftaf, Ahmad& Zhu, Zheng& Makramalla, Abouelmagd& Abdel Karim, Nagla. 2019. Nivolumab and Ipilimumab in the Treatment of Metastatic Uveal Melanoma: A Single-Center Experience. Case Reports in Oncological Medicine،Vol. 2019, no. 2019, pp.1-8.
https://search.emarefa.net/detail/BIM-1141923
Modern Language Association (MLA)
Karivedu, Vidhya…[et al.]. Nivolumab and Ipilimumab in the Treatment of Metastatic Uveal Melanoma: A Single-Center Experience. Case Reports in Oncological Medicine No. 2019 (2019), pp.1-8.
https://search.emarefa.net/detail/BIM-1141923
American Medical Association (AMA)
Karivedu, Vidhya& Eldessouki, Ihab& Taftaf, Ahmad& Zhu, Zheng& Makramalla, Abouelmagd& Abdel Karim, Nagla. Nivolumab and Ipilimumab in the Treatment of Metastatic Uveal Melanoma: A Single-Center Experience. Case Reports in Oncological Medicine. 2019. Vol. 2019, no. 2019, pp.1-8.
https://search.emarefa.net/detail/BIM-1141923
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1141923